Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Common purslane (Portulaca oleracea) is a nutritionally dense leafy green rich in alpha-linolenic acid (ALA), crude purslane polysaccharides (CPOP), betalains, and melatonin that reduce inflammatory cytokines TNF-α and IL-6 while enhancing antioxidant enzymes SOD, CAT, and GSH-Px. A comprehensive ethnopharmacological review confirmed its broad pharmacological activities including anti-inflammatory, antioxidant, antidiabetic, neuroprotective, and anticancer properties mediated through multiple molecular pathways (Li K et al., J Ethnopharmacol, 2024; PMID 37739100).
Reported Benefits (Provisional)
Origin & History
Common Purslane (Portulaca oleracea) is a succulent annual herb native to the Mediterranean region, now naturalized and cultivated worldwide. Revered for its nutritional density and resilience, it is a powerhouse of omega-3 fatty acids, vitamins, minerals, and potent antioxidants. In functional nutrition, purslane is highly valued for its comprehensive support of cardiovascular, cognitive, and digestive health.
Research Narrative (Provisional)
A 2024 comprehensive review by Li K et al. in the Journal of Ethnopharmacology (PMID 37739100) systematically catalogued purslane's phytochemistry and pharmacology, confirming its potent anti-inflammatory, antioxidant, hepatoprotective, and neuroprotective effects across in vitro and in vivo models. Heydarirad G et al. (2024) in Explore conducted a randomized, double-blind, placebo-controlled clinical trial (PMID 37872023) demonstrating the efficacy and safety of purslane for mild to moderate chronic hand eczema, providing direct human clinical evidence of its anti-inflammatory dermatological benefits. Amirul Alam M et al. (2014) in Molecular Biology Reports (PMID 25085039) highlighted genetic improvement strategies for purslane to enhance its omega-3 ALA content and nutritional profile for future food and nutraceutical applications. Additionally, Chandimali N et al. (2020) in Oncology Letters (PMID 32831922) demonstrated that BRM270, a botanical formulation containing Portulaca oleracea compounds, targets cancer stem cells and augments chemosensitivity, underscoring purslane's emerging anticancer potential.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Macronutrients: Alpha-Linolenic Acid (ALA) (high), Dietary Fiber - Vitamins: Vitamin A (as beta-carotene), Vitamin C, Vitamin E, B vitamins (trace) - Minerals: Magnesium, Calcium, Potassium, Iron, Manganese - Phytochemicals: Betalains, Flavonoids, Carotenoids (e.g., lutein), Glutathione - Bioactives: Melatonin
Reported Mechanism (Provisional)
Crude purslane polysaccharide (CPOP) exerts its anti-inflammatory effects by suppressing NF-κB signaling, directly reducing pro-inflammatory cytokines TNF-α and IL-6, while simultaneously enhancing insulin receptor substrate phosphorylation to improve insulin sensitivity. Purslane's alpha-linolenic acid (ALA) is metabolized to EPA and DHA via desaturase and elongase enzymes, competing with arachidonic acid in cyclooxygenase (COX) and lipoxygenase (LOX) pathways to shift eicosanoid production toward anti-inflammatory resolvins and protectins. The polysaccharide fraction POL-P3b induces mitochondrial-mediated apoptosis in cancer cells by upregulating pro-apoptotic Bax protein, downregulating anti-apoptotic Bcl-2, and activating caspase-3/caspase-9 cascades. Purslane's betalain pigments and flavonoids (kaempferol, quercetin, luteolin) scavenge reactive oxygen species (ROS) and upregulate endogenous antioxidant enzymes SOD, CAT, and GSH-Px through activation of the Nrf2/ARE signaling pathway.
Clinical Narrative (Provisional)
Evidence comes primarily from preclinical in vitro and animal studies, with limited human clinical trial data available. In diabetic rat models, CPOP at doses of 100-400 mg/kg significantly reduced fasting blood glucose and inflammatory markers while improving insulin sensitivity. Cancer cell studies showed POL-P3b at 100-200 µg/mL concentrations induced apoptosis in HeLa cells through specific molecular pathways. While preclinical results are promising for diabetes and cancer applications, large-scale human clinical trials with quantified outcomes are needed to establish clinical efficacy and safety profiles.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.